Your Messages Inbox
Your Article Summary
See Latest ArticlesCEL-SCI To Commence First Clinical Study With Hospitalized H1N1 Infected Patients
CEL-SCI, 10/21/09
CEL–SCI Corporation, a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late–stage oncology company, announced today that the U.S Food and Drug Administration has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS–H1N1 treatment on the white blood cells of hospitalized H1N1 patients. This followed the very responsive and expedited initial review of CEL–SCI's regulatory submission for this study proposal.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
Pandemic 2009 Influenza Update: Pandemrix data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline, 11/24/09
Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
Cephalon, 11/24/09
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/24/09
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
HealthPort Postpones its IPO
HealthDataManagement, 11/25/09
Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/24/09
Article Search
Sponsor